A reversibly gated effector polypeptide e.g. a chimeric antigen receptor (protease-activating CD45-gate CAR) comprising an extracellular CD45 recruiting domain, a protease-cleavable linker, and a polypeptide comprising an extracellular ligand binding domain, a transmembrane domain, and an intracellular domain. Nucleic acids including vectors and expression vectors that encode the protease-activating CD45-gate CAR and cells including immune cells such as T cells that comprise and express the nucleic acids. Methods of treatment of various conditions including various forms of cancer comprising administering the cells including CAR T cell therapy. In some embodiments, the CD45 gate at least partially inhibits activation of the protease-activating CD45-gate CAR when the protease-activating CD45-gate CAR binds antigen. The inhibition is at least partially diminished, relieved and/or eliminated when the protease-activating CD45-gate CAR is exposed to a protease that can cleave the linker.

Methods for prognosticating if an individual afflicted with a malignant tumor is likely to respond favorably to immunotherapy comprising testing for the presence or absence of DARC expression in the tumor, and if no DARC expression is detected, identifying the individual as not being suitable for immunotherapy, and optionally administering an anti-cancer therapy other than immunotherapy to the individual, or if DARC expression is detected, then identifying the individual as being suitable for immunotherapy, and optionally administering immunotherapy or any other anti-cancer therapy to the individual.

The present disclosure relates to a novel anti-HER2 antibody or an antigen-binding fragment thereof used in the prevention or treatment of cancer, a chimeric antigen receptor including the same, and uses thereof. The antibody of the present disclosure is an antibody that specifically binds to HER2 which is highly expressed in cancer cells (particularly, breast cancer or gastric cancer cells), and binds to an epitope that is different from an epitope to which trastuzumab binds.

The present invention relates to a chimeric antigen receptor (CAR) against programmed death ligand 1 (PD-L1) and application thereof. In particular, the CAR comprises an antigen-binding domain which binds to PD-L1; and the anti-PD-L1 CAR cells thus produced are useful in CAR cell therapy.

This invention is directed to engineered cells and methods for using the same. In embodiments, the engineered cell comprises a nucleic acid encoding a chimeric antigen receptor and a polypeptide, wherein the chimeric antigen receptor is specific for two or more antigens on the surface of a cancer cell, and wherein the polypeptide comprises an antibody or fragment thereof that can be secreted from the engineered cell.

The present invention relates to augmenting the effects of adoptive T cell therapy, such as TVAX Immunotherapy, using adjunct treatment with an oncolytic virus, such as a vaccinia virus, to treat various types of cancer or other proliferative disorders. Immunomodulatory compounds can be used to further augment to effects of the therapy.

Provided herein are polymeric particles and compositions (i.e., backpacks) that can adhere to cells and provide delivery of payload immunomodulatory agents to those cells. For examples, the particles can adhere to macrophages and/or monocytes and release cytokines that promote an M1 or M2 phenotype to improve therapeutic efficacy of the cells.

Provided herein are compositions and methods for cancer immunotherapy. In particular, provided herein are compositions and methods for blocking CD6 binding to ligands on cancer cells.

The presently disclosed subject matter provides for methods and compositions for treating cancer (e.g., breast cancer). It relates to mutant PIK3CA-targeted TCRs that specifically target a mutant PIK3CA peptide (e.g., a human mutant PIK3CA peptide), and immunoresponsive cells comprising such TCRs. The presently disclosed mutant PIK3CA peptide-specific TCRs have enhanced immune-activating properties, including anti-tumor activity.

Disclosed in the present invention is a genetically engineered cell, expressing an exogenous receptor that specifically binds to a target antigen and exogenous CCL21, and capable of further expressing an IL-7R binding protein or exogenous IL-7 that promotes cell proliferation. Also disclosed are an expression construct comprising an exogenous CCL21 expression cassette, and a vector containing same, a virus, and a pharmaceutical composition comprising said cell. Also disclosed is an application for the cell, the expression construct, the vector, and the virus in the preparation of drugs for inhibiting tumours or inhibiting pathogens.